Vol 8, No 4 (2019)
Research paper
Published online: 2019-08-14

open access

Page views 1507
Article views/downloads 1214
Get Citation

Connect on Social Media

Connect on Social Media

Impact of hyperglycaemia on molecular markers of oxidative stress and antioxidants in type 2 diabetes mellitus

Manidip Mandal1, Anila Varghese1, V.K. Gaviraju1, Sangamesh N. Talwar1, Suttur S. Malini1
Clin Diabetol 2019;8(4):215-222.

Abstract

Introduction. The pathogenesis of type 2 diabetes mel­litus (T2DM) is strongly linked to oxidative stress mainly caused by chronic hyperglycaemia. The present study investigates the association between hyperglycaemia with oxidative stress markers, antioxidants and lipid profile.

Materials and methods. The case-control study in­volved two groups, T2DM patients (n = 83) and age and sex matched controls (n = 81). Serum levels of various molecular markers malondialdehyde (MDA), reactive oxygen species (ROS) and nitric oxide (NO), su­peroxide dismutase (SOD), catalase (CAT), glutathione (GSH), vitamin C, total antioxidant capacity (TAC) and lipid parameters total cholesterol, triglycerides, low density lipoprotein (LDL) and high density lipoprotein (HDL) were measured using spectrophotometric as­says. Results were analysed to compare and correlate glycaemic levels with these molecular markers.

Results. T2DM patients had a higher body mass index (BMI) and body fat percentage. 2 hour blood glucose, glycated haemoglobin A1c % (HbA1c), total cholesterol, triglycerides and LDL were higher in diabetics, HDL was found to be lower in diabetics than in controls. Mean levels of enzymatic and non-enzymatic antioxi­dants SOD, CAT, GSH, vitamin C and TAC were signifi­cantly lower while oxidative stress markers NO, ROS and MDA were higher in T2DM patients. NO showed a positive correlation (r = 0.3993, p < 0.0001) whereas TAC showed a negative correlation with glycaemia (r = –0.4796, p < 0.0001).

Conclusions. Poor glycaemic control in T2DM causes elevated ROS and NO levels with increased lipid peroxi­dation and lowered antioxidant capacity. MDA and NO being the major risk factors could be used as a param­eter along with antioxidants to assess oxidative stress in T2DM patients.

Article available in PDF format

View PDF Download PDF file

References

  1. I V, M H. Introductory Chapter. In: Lushchak V, editor. Oxidative Stress — Molecular Mechanisms and Biological Effects. InTech. 2012.
  2. Brand MD. The sites and topology of mitochondrial superoxide production. Exp Gerontol. 2010; 45(7-8): 466–472.
  3. Feher J, Csomos G, Vereckei A. Control of Free Radical Reactions in Biological Systems. In: Free Radical Reactions in Medicine. Berlin, Heidelberg: Springer Berlin Heidelberg. 1987: 11–17.
  4. Noberasco G, Odetti P, Boeri D, et al. Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycosylated hemoglobin. Biomed Pharmacother. 1991; 45(4-5): 193–196.
  5. Niwa K, Takizawa S, Kawaguchi C, et al. Expression of inducible nitric oxide synthase immunoreactivity in rat brain following chronic hypoxia: effect of aminoguanidine. Neurosci Lett. 1999; 271(2): 109–112.
  6. Papapetropoulos A, García-Cardeña G, Madri JA, et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997; 100(12): 3131–3139.
  7. Warnick GR, Knopp RH, Fitzpatrick V, et al. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. 1990; 36(1): 15–19.
  8. Misra A, Chowbey P, Makkar BM, et al. Concensus Group. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009; 57: 163–170.
  9. Beyer WF, Fridovich I. Assaying for superoxide dismutase activity: some large consequences of minor changes in conditions. Anal Biochem. 1987; 161(2): 559–566.
  10. MORON M, DEPIERRE J, MANNERVIK B. Levels of glutathione, glutathione reductase and glutathione s-transferase activities in rat lung and liver. Biochimica et Biophysica Acta (BBA) — General Subjects. 1979; 582(1): 67–78.
  11. Cakmak I, Horst W. Effect of aluminium on lipid peroxidation, superoxide dismutase, catalase, and peroxidase activities in root tips of soybean (Glycine max). Physiologia Plantarum. 1991; 83(3): 463–468.
  12. Prieto P, Pineda M, Aguilar M. Spectrophotometric quantitation of antioxidant capacity through the formation of a phosphomolybdenum complex: specific application to the determination of vitamin E. Anal Biochem. 1999; 269(2): 337–341.
  13. BERNHEIM F, BERNHEIM MLC, WILBUR KM. The reaction between thiobarbituric acid and the oxidation products of certain lipides. J Biol Chem. 1948; 174(1): 257–264.
  14. Grisham MB, Johnson GG, Lancaster JR. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol. 1996; 268: 237–246.
  15. Black MJ, Brandt RB. Spectrofluorometric analysis of hydrogen peroxide. Anal Biochem. 1974; 58(1): 246–254.
  16. Karacay O, Sepici-Dincel A, Karcaaltincaba D, et al. A quantitative evaluation of total antioxidant status and oxidative stress markers in preeclampsia and gestational diabetic patients in 24–36 weeks of gestation. Diabetes Res Clin Pract. 2010; 89(3): 231–238.
  17. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107(9): 1058–1070.
  18. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009; 5(3): 150–159.
  19. American Diabetes Association. Standards of medical care in diabetes — 2010. Diabetes Care. 2010; 33 Suppl 1: S11–S61.
  20. Pasaoglu H, Sancak B, Bukan N. Lipid peroxidation and resistance to oxidation in patients with type 2 diabetes mellitus. Tohoku J Exp Med. 2004; 203(3): 211–218.
  21. Kesavulu MM, Rao BK, Giri R, et al. Lipid peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary heart disease. Diabetes Res Clin Pract. 2001; 53(1): 33–39.
  22. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia. 1997; 40(6): 647–653.
  23. Gallou G, Ruelland A, Legras B, et al. Plasma malondialdehyde in type 1 and type 2 diabetic patients. Clin Chim Acta. 1993; 214(2): 227–234.
  24. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 40(4): 405–412.
  25. Opara EC, Abdel-Rahman E, Soliman S, et al. Depletion of total antioxidant capacity in type 2 diabetes. Metabolism. 1999; 48(11): 1414–1417.
  26. Korkmaz GG, Konukoglu D, Kurtulus EM, et al. Total antioxidant status and markers of oxidative stress in subjects with normal or impaired glucose regulation (IFG, IGT) in diabetic patients. Scand J Clin Lab Invest. 2013; 73(8): 641–649.
  27. Savu O, Ionescu-Tirgoviste C, Atanasiu V, et al. Increase in total antioxidant capacity of plasma despite high levels of oxidative stress in uncomplicated type 2 diabetes mellitus. J Int Med Res. 2012; 40(2): 709–716.
  28. Maejima K, Nakano S, Himeno M, et al. Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications. 2001; 15(3): 135–143.
  29. Ozden S, Tatlipinar S, Biçer N, et al. Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy. Can J Ophthalmol. 2003; 38(5): 393–396.
  30. Ghosh A, Sherpa ML, Bhutia Y, et al. Serum nitric oxide status in patients with type 2 diabetes mellitus in Sikkim. Int J Appl Basic Med Res. 2011; 1(1): 31–35.
  31. Aouacheri O, Saka S, Krim M, et al. The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Can J Diabetes. 2015; 39(1): 44–49.